These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 24837828)
1. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828 [TBL] [Abstract][Full Text] [Related]
2. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509 [TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Tang JT; de Winter BC; Hesselink DA; Sombogaard F; Wang LL; van Gelder T Br J Clin Pharmacol; 2017 Apr; 83(4):812-822. PubMed ID: 27753146 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219 [TBL] [Abstract][Full Text] [Related]
5. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients. Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299 [TBL] [Abstract][Full Text] [Related]
6. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488 [TBL] [Abstract][Full Text] [Related]
7. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bremer S; Vethe NT; Rootwelt H; Jørgensen PF; Stenstrøm J; Holdaas H; Midtvedt K; Bergan S J Transl Med; 2009 Jul; 7():64. PubMed ID: 19635156 [TBL] [Abstract][Full Text] [Related]
8. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. van Hest RM; van Gelder T; Vulto AG; Mathot RA Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120 [TBL] [Abstract][Full Text] [Related]
11. The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5'-Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients. Thanukrishnan H; Venkataramanan R; Mehta RB; Jorgensen D; Sood P Clin Transplant; 2022 Dec; 36(12):e14830. PubMed ID: 36177865 [TBL] [Abstract][Full Text] [Related]
12. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019 [TBL] [Abstract][Full Text] [Related]
14. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953 [TBL] [Abstract][Full Text] [Related]
15. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503 [TBL] [Abstract][Full Text] [Related]
16. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785 [TBL] [Abstract][Full Text] [Related]
17. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients. Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555 [TBL] [Abstract][Full Text] [Related]
18. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356 [TBL] [Abstract][Full Text] [Related]